The Prostate Cancer Market Will Reach $12.5bn in 2020

Monday 6 June 2016, Amsterdam

A new report, now available on ASDReports, predicts that the prostate cancer market will reach $12.5bn in 2020. This forecast and others appear in The Prostate Cancer Market 2016-2026: Increasing Incidence and Promising New Therapies to Drive Market Growth, published in April 2016.

This report examines the current and future trends in the prostate cancer therapeutics market. Prostate cancer, also called carcinoma of the prostate, is a form of cancer which originates in the prostate; a walnut-shaped gland in the male reproductive system. The prostate is an exocrine gland located in the front of rectum and below the urinary bladder. Similarly to other types of cancer, carcinomas of the prostate advance through the blood and lymph nodes if left untreated. However, the rate of growth tends to be very slow compared to other cancers and research indicates that many older men develop at least a microscopic incident of prostate cancer. There has been much growth in the prostate cancer therapeutics market over the past decade, with a number of products targeting advanced forms of the disease and showing greatly increased efficacy over their predecessors. There are also a number of very promising therapies in the pipeline for both early and late stage prostate cancer, showing that there is still potential for growth in this market, particularly for treatments with reduced side-effects. This makes understanding the prostate cancer therapeutics market and the opportunities available crucial for all those in fields related to the sector.

In this report, we examine the sales of a wide range of therapeutics in the following submarkets: Prostate Cancer Drugs and Prostate Cancer Devices. An analysis of major drugs, with 10-year forecasts and upcoming pipeline candidates in the sector are also included for all of the major submarkets, along with analysis and forecasts for all major submarkets in the prostate cancer devices market.

The prospects for the twelve leading national markets in the prostate cancer market, including the US, Germany, France, Italy, Spain, the UK, Japan, China, India, Russia, Brazil and South Korea. Using both primary and secondary research, forecasts have been built for the major submarkets, leading drugs and leading national and regional markets, accompanied by text giving a thorough explanation of events thought to shape the market currently and in the future.

Also included is analysis of the current leading players in the prostate cancer therapeutics market. Historical financial performance over 5 years is analysed (where available), along with a breakdown of each company’s leading products, leading pipeline candidates and recent merger & acquisition information, with an analysis of news that may influence the course of the company.